Last reviewed · How we verify
bevacizumab plus chemotherapy
Bevacizumab is a monoclonal antibody that inhibits angiogenesis by binding to vascular endothelial growth factor A (VEGF-A), thereby preventing tumor growth and metastasis.
Bevacizumab is a monoclonal antibody that inhibits angiogenesis by binding to vascular endothelial growth factor A (VEGF-A), thereby preventing tumor growth and metastasis. Used for Metastatic colorectal cancer, Non-small cell lung cancer, Breast cancer.
At a glance
| Generic name | bevacizumab plus chemotherapy |
|---|---|
| Sponsor | Liaoning Cancer Hospital & Institute |
| Drug class | Angiogenesis inhibitor |
| Target | VEGF-A |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | Phase 3 |
Mechanism of action
Bevacizumab works by targeting the VEGF-A protein, which is involved in the formation of new blood vessels that supply nutrients to growing tumors. By inhibiting VEGF-A, bevacizumab reduces tumor growth and metastasis. When used in combination with chemotherapy, bevacizumab can enhance the effectiveness of the treatment.
Approved indications
- Metastatic colorectal cancer
- Non-small cell lung cancer
- Breast cancer
- Glioblastoma
- Renal cell carcinoma
Common side effects
- Hypertension
- Nausea
- Diarrhea
- Fatigue
- Headache
Key clinical trials
- Paclitaxel and Carboplatin With or Without Bevacizumab in Treating Patients With Stage II, Stage III, or Stage IV Ovarian Epithelial Cancer, Primary Peritoneal Cancer, or Fallopian Tube Cancer (PHASE3)
- A Study to Evaluate the Efficacy and Safety of Sacituzumab Tirumotecan (MK-2870) Maintenance Treatment Versus Standard of Care in Participants With Platinum-sensitive Recurrent Ovarian Cancer (MK-2870-022/TroFuse-022/ENGOT-ov84/GOG-3103) (PHASE3)
- Testing the Addition of an Antiangiogenic Drug (Bevacizumab) to Chemotherapy (Carboplatin and Paclitaxel) Combined With Immunotherapy (Pembrolizumab) for pMMR, TP53 Mutated Endometrial Cancer (PHASE3)
- A Study to Determine Whether Chemotherapy and Atezolizumab is Better Than Chemotherapy, Bevacizumab and Atezolizumab in Patients With Advanced Liver Cancer (PHASE2)
- Testing the Addition of Atezolizumab to Combination Chemotherapy or Atezolizumab Alone for Metastatic Colon or Rectal Cancer, the COMMIT Study (PHASE3)
- Clinical Trial of an Anti-cancer Drug, CA-4948 (Emavusertib), in Combination With Chemotherapy Treatment (FOLFOX Plus Bevacizumab) in Metastatic Colorectal Cancer (PHASE1)
- HAIC Plus Systemic Therapy as De-escalation Therapy Strategy for Biliary Tract Cancer (NA)
- A Clinical Study of Raludotatug Deruxtecan in People With Ovarian Cancer (MK-5909-003) (PHASE1, PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- bevacizumab plus chemotherapy CI brief — competitive landscape report
- bevacizumab plus chemotherapy updates RSS · CI watch RSS
- Liaoning Cancer Hospital & Institute portfolio CI